Year Founded
2016
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Bispecific antibody

Phanes Therapeutics General Information

Early-stage biotech company developing bispecific antibody platforms for immuno-oncology applications

Contact Information

Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States

Drug Pipeline

PT217
Clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Phanes Therapeutics's pipeline data

Book a demo

Key Partnerships

Roche

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Phanes Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Phanes Therapeutics's complete valuation and funding history, request access »